7/22/2010

GE Global Research and Memorial Sloan-Kettering Cancer Center in New York have partnered to study biomarkers that will help differentiate between high-risk and low-risk colon cancer, particularly during its early phase. Researchers will evaluate molecular profiles for cancer tissues and their relation to treatment results.

Related Summaries